Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00243_DB00257_nanopub.RAmMyYwucOkmQ16Eov2BMFrfjdkik4Suy3oFdFLkw6Irw#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00243_DB00257 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00243_DB00257 label "DDI between Ranolazine and Clotrimazole - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use. [drugbank_resource:DB00243_DB00257]" assertion.
- drugbank_resource:DB00243_DB00257 identifier "drugbank_resource:DB00243_DB00257" assertion.
- drugbank_resource:DB00243_DB00257 title "DDI between Ranolazine and Clotrimazole - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use." assertion.
- drugbank:DB00257 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00243_DB00257 assertion.
- drugbank:DB00243 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00243_DB00257 assertion.